ESG Reporting Requirements for Emerging Biotechs

3:30 PM - 4:30 PM (PDT), Monday, June 13, 2022 ・ Upper Level, Session Room 7B

Environmental, social, and governance (“ESG”) issues are gaining significant attention from investors, but few development-stage, publicly traded biotech companies include these topics in their regulatory filings or issue separate reports for stakeholders and investors.   However, there is no consensus on what ESG should mean for development-stage companies.  This panel will discuss current sticking points for these companies and how recent EU and SEC disclosure rules impact reporting and the path forward.